NCT07870824 A Study to Investigate the Effect of Probiotics (Limosilactobacillus Reuteri DSM 17938 and Limosilactobacillus Reuteri DSM 33633) on Symptoms of Viral Upper Respiratory Tract Infections in Children
| NCT ID | NCT07870824 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Milosevits Gergely |
| Condition | Virus Diseases in Children |
| Study Type | INTERVENTIONAL |
| Enrollment | 194 participants |
| Start Date | 2026-10-19 |
| Primary Completion | 2028-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 194 participants in total. It began in 2026-10-19 with a primary completion date of 2028-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates the effect of Limosilactobacillus reuteri probiotic strains (DSM 17938 and DSM 33633) on symptoms of viral upper-respiratory tract infections in children.
Eligibility Criteria
Inclusion Criteria: * Children with symptoms of upper respiratory tract infection (coughing/fever/sneezing/runny or congested nose/pharynx pain) * Any gender * Age from 4 years to 17 years * Signing a informed consent form by at least one parent, foster parent or guardian after patient information and by children aged over 6 years * Negative Strep test Exclusion Criteria: * Use of antibiotics or probiotics in the 10 days prior to study enrolment * Use of a probiotic other than the test sample during the study * Eight or more otitis media within 12 months * Two or more bacterial sinusitis within 12 months * Two or more pneumonia episodes within 12 months * History of two or more invasive infections (meningitis, cellulitis, osteomyelitis, septicaemia) * Chronic diarrhea * Recurrent deep skin or organ abscesses * Persistent superficial candidiasis * Use of antibiotics for two months or more to treat respiratory infections within 12 months * Gastroesophageal reflux * Perennial (e.g., dust mite or mold) or current seasonal hay fever allergy * Primary or secondary ciliary dyskinesia * Congenital malformations of the respiratory tract
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07870824 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 17 Years, studying Virus Diseases in Children. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07870824 currently recruiting?
Yes, NCT07870824 is actively recruiting participants. Contact the research team at drgergelymilosevits@gmail.com for enrollment information.
Where is the NCT07870824 trial being conducted?
This trial is being conducted at Szigetszentmiklós, Hungary.
Who is sponsoring the NCT07870824 clinical trial?
NCT07870824 is sponsored by Milosevits Gergely. The trial plans to enroll 194 participants.